Global Prostate Cancer Diagnostics

Prostate Cancer Diagnostics Comprehensive Study by Type (Tumor Biomarker Tests, Imaging, Biopsy, Other), Treatment (Surveillance, Localized Therapy, Systemic Therapy, Others), Test Type (Preliminary Tests, Confirmatory Tests, PCA3 Tests, Trans-rectal Ultrasound, Biopsy, Others), Modality (Diagnosis, Treatment), Age (< 55 years, 55-75, > 75), End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others) Players and Region - Global Market Outlook to 2030

Prostate Cancer Diagnostics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Prostate Cancer Diagnostics
The prostate is a small walnut-shaped gland in the pelvis of men and Prostate cancer is a form of cancer that develops in the prostate gland. Prostate cancer diagnostics is the way for the doctor to know an area of the body has cancer. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread. Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy, and others to diagnose whether patients with breast cancer. According to the research, Prostate cancer is very common, showing up in 240,000 U.S. men every year. It kills about 30,000 a year. In most men, prostate cancer isn't likely to kill them before something else does. growing Aging Population and High Prevalence Rate of Prostate Cancer is booming the market demand

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global Prostate Cancer Diagnostics market is fragmented due to the presence of regional and global manufacturers. The level of competition among the companies in the Prostate Cancer Diagnostics market is intense and manufacturers focus on developing new technologies and offering customized products to the customers. In the coming years, manufacturers will also develop new partnerships to spread their product reach to more customers globally. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Prostate Cancer Diagnostics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Genomic Health (United States), Abbott (United States), OPKO (United States), Siemens Healthcare (Germany), DiaSorin (Italy), BioMeriux (France), Roche (Switzerlan), MDx Health (Belgium), Beckman Coulter (United States), Myriad Genetics (United States) and Ambry Genetics (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Farmasol (Turkey), Maquet (Russia) and Kawasumi (United States).

Segmentation Overview
AMA Research has segmented the market of Global Prostate Cancer Diagnostics market by Type (Tumor Biomarker Tests, Imaging, Biopsy and Other) and Region.



On the basis of geography, the market of Prostate Cancer Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Surveillance will boost the Prostate Cancer Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Test Type, the sub-segment i.e. Preliminary Tests will boost the Prostate Cancer Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Modality, the sub-segment i.e. Diagnosis will boost the Prostate Cancer Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Age, the sub-segment i.e. < 55 years will boost the Prostate Cancer Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital Associated Labs will boost the Prostate Cancer Diagnostics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Emerging demand for Prostate Specific Antigen(PSA)testing

Market Growth Drivers:
Growing Government Initiatives for Cancer Awareness and Rising prevalence of disease requiring surgical treatment and Cancer and the growing number of bariatric surgeries is the key driving factor of growth

Challenges:
Erectile Dysfunction After Prostate Surgery

Restraints:
High Cost Of Prostate Cancer Treatment

Opportunities:
Technological advancements in the healthcare sector and increasing prevalence of the disease and use of AI tools for identifying suspicious areas is booming the opportunities of growth

Market Leaders and their expansionary development strategies
In August 2022, MDxHealth said on Tuesday that it has acquired the Oncotype DX GPS prostate cancer testing business from Exact Sciences subsidiary Genomic Health
July 13, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, today announced the launch of a novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in collaboration with Envision Sciences. Envision Sciences Pty Ltd. is an Australian-based clinical diagnostics company developing a pipeline of biomarker-based cancer diagnostic and prognostic tests in tissue and blood.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Prostate Cancer DiagnosticsManufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Tumor Biomarker Tests
  • Imaging
  • Biopsy
  • Other
By Treatment
  • Surveillance
  • Localized Therapy
  • Systemic Therapy
  • Others

By Test Type
  • Preliminary Tests
  • Confirmatory Tests
  • PCA3 Tests
  • Trans-rectal Ultrasound
  • Biopsy
  • Others

By Modality
  • Diagnosis
  • Treatment

By Age
  • < 55 years
  • 55-75
  • > 75

By End User
  • Hospital Associated Labs
  • Independent Diagnostic Laboratories
  • Cancer Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Government Initiatives for Cancer Awareness
      • 3.2.2. Rising prevalence of disease requiring surgical treatment and Cancer and the growing number of bariatric surgeries is the key driving factor of growth
    • 3.3. Market Challenges
      • 3.3.1. Erectile Dysfunction After Prostate Surgery
    • 3.4. Market Trends
      • 3.4.1. Emerging demand for Prostate Specific Antigen(PSA)testing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Prostate Cancer Diagnostics, by Type, Treatment, Test Type, Modality, Age, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Prostate Cancer Diagnostics (Value)
      • 5.2.1. Global Prostate Cancer Diagnostics by: Type (Value)
        • 5.2.1.1. Tumor Biomarker Tests
        • 5.2.1.2. Imaging
        • 5.2.1.3. Biopsy
        • 5.2.1.4. Other
      • 5.2.2. Global Prostate Cancer Diagnostics by: Treatment (Value)
        • 5.2.2.1. Surveillance
        • 5.2.2.2. Localized Therapy
        • 5.2.2.3. Systemic Therapy
        • 5.2.2.4. Others
      • 5.2.3. Global Prostate Cancer Diagnostics by: Test Type (Value)
        • 5.2.3.1. Preliminary Tests
        • 5.2.3.2. Confirmatory Tests
        • 5.2.3.3. PCA3 Tests
        • 5.2.3.4. Trans-rectal Ultrasound
        • 5.2.3.5. Biopsy
        • 5.2.3.6. Others
      • 5.2.4. Global Prostate Cancer Diagnostics by: Modality (Value)
        • 5.2.4.1. Diagnosis
        • 5.2.4.2. Treatment
      • 5.2.5. Global Prostate Cancer Diagnostics by: Age (Value)
        • 5.2.5.1. < 55 years
        • 5.2.5.2. 55-75
        • 5.2.5.3. > 75
      • 5.2.6. Global Prostate Cancer Diagnostics by: End User (Value)
        • 5.2.6.1. Hospital Associated Labs
        • 5.2.6.2. Independent Diagnostic Laboratories
        • 5.2.6.3. Cancer Research Institutes
        • 5.2.6.4. Others
      • 5.2.7. Global Prostate Cancer Diagnostics Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Prostate Cancer Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Genomic Health (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. OPKO (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Siemens Healthcare (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. DiaSorin (Italy)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BioMeriux (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Roche (Switzerlan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. MDx Health (Belgium)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Beckman Coulter (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Myriad Genetics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Ambry Genetics (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Prostate Cancer Diagnostics Sale, by Type, Treatment, Test Type, Modality, Age, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Prostate Cancer Diagnostics (Value)
      • 7.2.1. Global Prostate Cancer Diagnostics by: Type (Value)
        • 7.2.1.1. Tumor Biomarker Tests
        • 7.2.1.2. Imaging
        • 7.2.1.3. Biopsy
        • 7.2.1.4. Other
      • 7.2.2. Global Prostate Cancer Diagnostics by: Treatment (Value)
        • 7.2.2.1. Surveillance
        • 7.2.2.2. Localized Therapy
        • 7.2.2.3. Systemic Therapy
        • 7.2.2.4. Others
      • 7.2.3. Global Prostate Cancer Diagnostics by: Test Type (Value)
        • 7.2.3.1. Preliminary Tests
        • 7.2.3.2. Confirmatory Tests
        • 7.2.3.3. PCA3 Tests
        • 7.2.3.4. Trans-rectal Ultrasound
        • 7.2.3.5. Biopsy
        • 7.2.3.6. Others
      • 7.2.4. Global Prostate Cancer Diagnostics by: Modality (Value)
        • 7.2.4.1. Diagnosis
        • 7.2.4.2. Treatment
      • 7.2.5. Global Prostate Cancer Diagnostics by: Age (Value)
        • 7.2.5.1. < 55 years
        • 7.2.5.2. 55-75
        • 7.2.5.3. > 75
      • 7.2.6. Global Prostate Cancer Diagnostics by: End User (Value)
        • 7.2.6.1. Hospital Associated Labs
        • 7.2.6.2. Independent Diagnostic Laboratories
        • 7.2.6.3. Cancer Research Institutes
        • 7.2.6.4. Others
      • 7.2.7. Global Prostate Cancer Diagnostics Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Prostate Cancer Diagnostics: by Type(USD Million)
  • Table 2. Prostate Cancer Diagnostics Tumor Biomarker Tests , by Region USD Million (2018-2023)
  • Table 3. Prostate Cancer Diagnostics Imaging , by Region USD Million (2018-2023)
  • Table 4. Prostate Cancer Diagnostics Biopsy , by Region USD Million (2018-2023)
  • Table 5. Prostate Cancer Diagnostics Other , by Region USD Million (2018-2023)
  • Table 6. Prostate Cancer Diagnostics: by Treatment(USD Million)
  • Table 7. Prostate Cancer Diagnostics Surveillance , by Region USD Million (2018-2023)
  • Table 8. Prostate Cancer Diagnostics Localized Therapy , by Region USD Million (2018-2023)
  • Table 9. Prostate Cancer Diagnostics Systemic Therapy , by Region USD Million (2018-2023)
  • Table 10. Prostate Cancer Diagnostics Others , by Region USD Million (2018-2023)
  • Table 11. Prostate Cancer Diagnostics: by Test Type(USD Million)
  • Table 12. Prostate Cancer Diagnostics Preliminary Tests , by Region USD Million (2018-2023)
  • Table 13. Prostate Cancer Diagnostics Confirmatory Tests , by Region USD Million (2018-2023)
  • Table 14. Prostate Cancer Diagnostics PCA3 Tests , by Region USD Million (2018-2023)
  • Table 15. Prostate Cancer Diagnostics Trans-rectal Ultrasound , by Region USD Million (2018-2023)
  • Table 16. Prostate Cancer Diagnostics Biopsy , by Region USD Million (2018-2023)
  • Table 17. Prostate Cancer Diagnostics Others , by Region USD Million (2018-2023)
  • Table 18. Prostate Cancer Diagnostics: by Modality(USD Million)
  • Table 19. Prostate Cancer Diagnostics Diagnosis , by Region USD Million (2018-2023)
  • Table 20. Prostate Cancer Diagnostics Treatment , by Region USD Million (2018-2023)
  • Table 21. Prostate Cancer Diagnostics: by Age(USD Million)
  • Table 22. Prostate Cancer Diagnostics < 55 years , by Region USD Million (2018-2023)
  • Table 23. Prostate Cancer Diagnostics 55-75 , by Region USD Million (2018-2023)
  • Table 24. Prostate Cancer Diagnostics > 75 , by Region USD Million (2018-2023)
  • Table 25. Prostate Cancer Diagnostics: by End User(USD Million)
  • Table 26. Prostate Cancer Diagnostics Hospital Associated Labs , by Region USD Million (2018-2023)
  • Table 27. Prostate Cancer Diagnostics Independent Diagnostic Laboratories , by Region USD Million (2018-2023)
  • Table 28. Prostate Cancer Diagnostics Cancer Research Institutes , by Region USD Million (2018-2023)
  • Table 29. Prostate Cancer Diagnostics Others , by Region USD Million (2018-2023)
  • Table 30. South America Prostate Cancer Diagnostics, by Country USD Million (2018-2023)
  • Table 31. South America Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 32. South America Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 33. South America Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 34. South America Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 35. South America Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 36. South America Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 37. Brazil Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 38. Brazil Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 39. Brazil Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 40. Brazil Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 41. Brazil Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 42. Brazil Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 43. Argentina Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 44. Argentina Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 45. Argentina Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 46. Argentina Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 47. Argentina Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 48. Argentina Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 49. Rest of South America Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 50. Rest of South America Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 51. Rest of South America Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 52. Rest of South America Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 53. Rest of South America Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 54. Rest of South America Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 55. Asia Pacific Prostate Cancer Diagnostics, by Country USD Million (2018-2023)
  • Table 56. Asia Pacific Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 57. Asia Pacific Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 58. Asia Pacific Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 59. Asia Pacific Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 60. Asia Pacific Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 61. Asia Pacific Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 62. China Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 63. China Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 64. China Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 65. China Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 66. China Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 67. China Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 68. Japan Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 69. Japan Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 70. Japan Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 71. Japan Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 72. Japan Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 73. Japan Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 74. India Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 75. India Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 76. India Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 77. India Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 78. India Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 79. India Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 80. South Korea Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 81. South Korea Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 82. South Korea Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 83. South Korea Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 84. South Korea Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 85. South Korea Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 86. Taiwan Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 87. Taiwan Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 88. Taiwan Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 89. Taiwan Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 90. Taiwan Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 91. Taiwan Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 92. Australia Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 93. Australia Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 94. Australia Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 95. Australia Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 96. Australia Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 97. Australia Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 98. Rest of Asia-Pacific Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 99. Rest of Asia-Pacific Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 100. Rest of Asia-Pacific Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 101. Rest of Asia-Pacific Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 102. Rest of Asia-Pacific Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 103. Rest of Asia-Pacific Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 104. Europe Prostate Cancer Diagnostics, by Country USD Million (2018-2023)
  • Table 105. Europe Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 106. Europe Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 107. Europe Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 108. Europe Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 109. Europe Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 110. Europe Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 111. Germany Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 112. Germany Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 113. Germany Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 114. Germany Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 115. Germany Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 116. Germany Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 117. France Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 118. France Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 119. France Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 120. France Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 121. France Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 122. France Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 123. Italy Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 124. Italy Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 125. Italy Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 126. Italy Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 127. Italy Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 128. Italy Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 129. United Kingdom Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 130. United Kingdom Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 131. United Kingdom Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 132. United Kingdom Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 133. United Kingdom Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 134. United Kingdom Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 135. Netherlands Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 136. Netherlands Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 137. Netherlands Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 138. Netherlands Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 139. Netherlands Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 140. Netherlands Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 141. Rest of Europe Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 142. Rest of Europe Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 143. Rest of Europe Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 144. Rest of Europe Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 145. Rest of Europe Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 146. Rest of Europe Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 147. MEA Prostate Cancer Diagnostics, by Country USD Million (2018-2023)
  • Table 148. MEA Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 149. MEA Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 150. MEA Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 151. MEA Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 152. MEA Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 153. MEA Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 154. Middle East Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 155. Middle East Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 156. Middle East Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 157. Middle East Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 158. Middle East Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 159. Middle East Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 160. Africa Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 161. Africa Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 162. Africa Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 163. Africa Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 164. Africa Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 165. Africa Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 166. North America Prostate Cancer Diagnostics, by Country USD Million (2018-2023)
  • Table 167. North America Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 168. North America Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 169. North America Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 170. North America Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 171. North America Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 172. North America Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 173. United States Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 174. United States Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 175. United States Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 176. United States Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 177. United States Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 178. United States Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 179. Canada Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 180. Canada Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 181. Canada Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 182. Canada Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 183. Canada Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 184. Canada Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 185. Mexico Prostate Cancer Diagnostics, by Type USD Million (2018-2023)
  • Table 186. Mexico Prostate Cancer Diagnostics, by Treatment USD Million (2018-2023)
  • Table 187. Mexico Prostate Cancer Diagnostics, by Test Type USD Million (2018-2023)
  • Table 188. Mexico Prostate Cancer Diagnostics, by Modality USD Million (2018-2023)
  • Table 189. Mexico Prostate Cancer Diagnostics, by Age USD Million (2018-2023)
  • Table 190. Mexico Prostate Cancer Diagnostics, by End User USD Million (2018-2023)
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Prostate Cancer Diagnostics: by Type(USD Million)
  • Table 203. Prostate Cancer Diagnostics Tumor Biomarker Tests , by Region USD Million (2025-2030)
  • Table 204. Prostate Cancer Diagnostics Imaging , by Region USD Million (2025-2030)
  • Table 205. Prostate Cancer Diagnostics Biopsy , by Region USD Million (2025-2030)
  • Table 206. Prostate Cancer Diagnostics Other , by Region USD Million (2025-2030)
  • Table 207. Prostate Cancer Diagnostics: by Treatment(USD Million)
  • Table 208. Prostate Cancer Diagnostics Surveillance , by Region USD Million (2025-2030)
  • Table 209. Prostate Cancer Diagnostics Localized Therapy , by Region USD Million (2025-2030)
  • Table 210. Prostate Cancer Diagnostics Systemic Therapy , by Region USD Million (2025-2030)
  • Table 211. Prostate Cancer Diagnostics Others , by Region USD Million (2025-2030)
  • Table 212. Prostate Cancer Diagnostics: by Test Type(USD Million)
  • Table 213. Prostate Cancer Diagnostics Preliminary Tests , by Region USD Million (2025-2030)
  • Table 214. Prostate Cancer Diagnostics Confirmatory Tests , by Region USD Million (2025-2030)
  • Table 215. Prostate Cancer Diagnostics PCA3 Tests , by Region USD Million (2025-2030)
  • Table 216. Prostate Cancer Diagnostics Trans-rectal Ultrasound , by Region USD Million (2025-2030)
  • Table 217. Prostate Cancer Diagnostics Biopsy , by Region USD Million (2025-2030)
  • Table 218. Prostate Cancer Diagnostics Others , by Region USD Million (2025-2030)
  • Table 219. Prostate Cancer Diagnostics: by Modality(USD Million)
  • Table 220. Prostate Cancer Diagnostics Diagnosis , by Region USD Million (2025-2030)
  • Table 221. Prostate Cancer Diagnostics Treatment , by Region USD Million (2025-2030)
  • Table 222. Prostate Cancer Diagnostics: by Age(USD Million)
  • Table 223. Prostate Cancer Diagnostics < 55 years , by Region USD Million (2025-2030)
  • Table 224. Prostate Cancer Diagnostics 55-75 , by Region USD Million (2025-2030)
  • Table 225. Prostate Cancer Diagnostics > 75 , by Region USD Million (2025-2030)
  • Table 226. Prostate Cancer Diagnostics: by End User(USD Million)
  • Table 227. Prostate Cancer Diagnostics Hospital Associated Labs , by Region USD Million (2025-2030)
  • Table 228. Prostate Cancer Diagnostics Independent Diagnostic Laboratories , by Region USD Million (2025-2030)
  • Table 229. Prostate Cancer Diagnostics Cancer Research Institutes , by Region USD Million (2025-2030)
  • Table 230. Prostate Cancer Diagnostics Others , by Region USD Million (2025-2030)
  • Table 231. South America Prostate Cancer Diagnostics, by Country USD Million (2025-2030)
  • Table 232. South America Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 233. South America Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 234. South America Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 235. South America Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 236. South America Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 237. South America Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 238. Brazil Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 239. Brazil Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 240. Brazil Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 241. Brazil Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 242. Brazil Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 243. Brazil Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 244. Argentina Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 245. Argentina Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 246. Argentina Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 247. Argentina Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 248. Argentina Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 249. Argentina Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 250. Rest of South America Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 251. Rest of South America Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 252. Rest of South America Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 253. Rest of South America Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 254. Rest of South America Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 255. Rest of South America Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 256. Asia Pacific Prostate Cancer Diagnostics, by Country USD Million (2025-2030)
  • Table 257. Asia Pacific Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 258. Asia Pacific Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 259. Asia Pacific Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 260. Asia Pacific Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 261. Asia Pacific Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 262. Asia Pacific Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 263. China Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 264. China Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 265. China Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 266. China Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 267. China Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 268. China Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 269. Japan Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 270. Japan Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 271. Japan Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 272. Japan Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 273. Japan Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 274. Japan Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 275. India Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 276. India Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 277. India Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 278. India Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 279. India Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 280. India Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 281. South Korea Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 282. South Korea Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 283. South Korea Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 284. South Korea Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 285. South Korea Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 286. South Korea Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 287. Taiwan Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 288. Taiwan Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 289. Taiwan Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 290. Taiwan Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 291. Taiwan Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 292. Taiwan Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 293. Australia Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 294. Australia Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 295. Australia Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 296. Australia Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 297. Australia Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 298. Australia Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 299. Rest of Asia-Pacific Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 300. Rest of Asia-Pacific Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 301. Rest of Asia-Pacific Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 302. Rest of Asia-Pacific Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 303. Rest of Asia-Pacific Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 304. Rest of Asia-Pacific Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 305. Europe Prostate Cancer Diagnostics, by Country USD Million (2025-2030)
  • Table 306. Europe Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 307. Europe Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 308. Europe Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 309. Europe Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 310. Europe Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 311. Europe Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 312. Germany Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 313. Germany Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 314. Germany Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 315. Germany Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 316. Germany Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 317. Germany Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 318. France Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 319. France Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 320. France Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 321. France Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 322. France Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 323. France Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 324. Italy Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 325. Italy Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 326. Italy Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 327. Italy Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 328. Italy Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 329. Italy Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 330. United Kingdom Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 331. United Kingdom Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 332. United Kingdom Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 333. United Kingdom Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 334. United Kingdom Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 335. United Kingdom Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 336. Netherlands Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 337. Netherlands Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 338. Netherlands Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 339. Netherlands Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 340. Netherlands Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 341. Netherlands Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 342. Rest of Europe Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 343. Rest of Europe Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 344. Rest of Europe Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 345. Rest of Europe Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 346. Rest of Europe Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 347. Rest of Europe Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 348. MEA Prostate Cancer Diagnostics, by Country USD Million (2025-2030)
  • Table 349. MEA Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 350. MEA Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 351. MEA Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 352. MEA Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 353. MEA Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 354. MEA Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 355. Middle East Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 356. Middle East Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 357. Middle East Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 358. Middle East Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 359. Middle East Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 360. Middle East Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 361. Africa Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 362. Africa Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 363. Africa Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 364. Africa Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 365. Africa Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 366. Africa Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 367. North America Prostate Cancer Diagnostics, by Country USD Million (2025-2030)
  • Table 368. North America Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 369. North America Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 370. North America Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 371. North America Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 372. North America Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 373. North America Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 374. United States Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 375. United States Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 376. United States Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 377. United States Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 378. United States Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 379. United States Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 380. Canada Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 381. Canada Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 382. Canada Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 383. Canada Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 384. Canada Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 385. Canada Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 386. Mexico Prostate Cancer Diagnostics, by Type USD Million (2025-2030)
  • Table 387. Mexico Prostate Cancer Diagnostics, by Treatment USD Million (2025-2030)
  • Table 388. Mexico Prostate Cancer Diagnostics, by Test Type USD Million (2025-2030)
  • Table 389. Mexico Prostate Cancer Diagnostics, by Modality USD Million (2025-2030)
  • Table 390. Mexico Prostate Cancer Diagnostics, by Age USD Million (2025-2030)
  • Table 391. Mexico Prostate Cancer Diagnostics, by End User USD Million (2025-2030)
  • Table 392. Research Programs/Design for This Report
  • Table 393. Key Data Information from Secondary Sources
  • Table 394. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Prostate Cancer Diagnostics: by Type USD Million (2018-2023)
  • Figure 5. Global Prostate Cancer Diagnostics: by Treatment USD Million (2018-2023)
  • Figure 6. Global Prostate Cancer Diagnostics: by Test Type USD Million (2018-2023)
  • Figure 7. Global Prostate Cancer Diagnostics: by Modality USD Million (2018-2023)
  • Figure 8. Global Prostate Cancer Diagnostics: by Age USD Million (2018-2023)
  • Figure 9. Global Prostate Cancer Diagnostics: by End User USD Million (2018-2023)
  • Figure 10. South America Prostate Cancer Diagnostics Share (%), by Country
  • Figure 11. Asia Pacific Prostate Cancer Diagnostics Share (%), by Country
  • Figure 12. Europe Prostate Cancer Diagnostics Share (%), by Country
  • Figure 13. MEA Prostate Cancer Diagnostics Share (%), by Country
  • Figure 14. North America Prostate Cancer Diagnostics Share (%), by Country
  • Figure 15. Global Prostate Cancer Diagnostics share by Players 2023 (%)
  • Figure 16. Global Prostate Cancer Diagnostics share by Players (Top 3) 2023(%)
  • Figure 17. Global Prostate Cancer Diagnostics share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Genomic Health (United States) Revenue, Net Income and Gross profit
  • Figure 20. Genomic Health (United States) Revenue: by Geography 2023
  • Figure 21. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 22. Abbott (United States) Revenue: by Geography 2023
  • Figure 23. OPKO (United States) Revenue, Net Income and Gross profit
  • Figure 24. OPKO (United States) Revenue: by Geography 2023
  • Figure 25. Siemens Healthcare (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Siemens Healthcare (Germany) Revenue: by Geography 2023
  • Figure 27. DiaSorin (Italy) Revenue, Net Income and Gross profit
  • Figure 28. DiaSorin (Italy) Revenue: by Geography 2023
  • Figure 29. BioMeriux (France) Revenue, Net Income and Gross profit
  • Figure 30. BioMeriux (France) Revenue: by Geography 2023
  • Figure 31. Roche (Switzerlan) Revenue, Net Income and Gross profit
  • Figure 32. Roche (Switzerlan) Revenue: by Geography 2023
  • Figure 33. MDx Health (Belgium) Revenue, Net Income and Gross profit
  • Figure 34. MDx Health (Belgium) Revenue: by Geography 2023
  • Figure 35. Beckman Coulter (United States) Revenue, Net Income and Gross profit
  • Figure 36. Beckman Coulter (United States) Revenue: by Geography 2023
  • Figure 37. Myriad Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 38. Myriad Genetics (United States) Revenue: by Geography 2023
  • Figure 39. Ambry Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 40. Ambry Genetics (United States) Revenue: by Geography 2023
  • Figure 41. Global Prostate Cancer Diagnostics: by Type USD Million (2025-2030)
  • Figure 42. Global Prostate Cancer Diagnostics: by Treatment USD Million (2025-2030)
  • Figure 43. Global Prostate Cancer Diagnostics: by Test Type USD Million (2025-2030)
  • Figure 44. Global Prostate Cancer Diagnostics: by Modality USD Million (2025-2030)
  • Figure 45. Global Prostate Cancer Diagnostics: by Age USD Million (2025-2030)
  • Figure 46. Global Prostate Cancer Diagnostics: by End User USD Million (2025-2030)
  • Figure 47. South America Prostate Cancer Diagnostics Share (%), by Country
  • Figure 48. Asia Pacific Prostate Cancer Diagnostics Share (%), by Country
  • Figure 49. Europe Prostate Cancer Diagnostics Share (%), by Country
  • Figure 50. MEA Prostate Cancer Diagnostics Share (%), by Country
  • Figure 51. North America Prostate Cancer Diagnostics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Genomic Health (United States)
  • Abbott (United States)
  • OPKO (United States)
  • Siemens Healthcare (Germany)
  • DiaSorin (Italy)
  • BioMeriux (France)
  • Roche (Switzerlan)
  • MDx Health (Belgium)
  • Beckman Coulter (United States)
  • Myriad Genetics (United States)
  • Ambry Genetics (United States)
Additional players considered in the study are as follows:
Farmasol (Turkey) , Maquet (Russia) , Kawasumi (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 220 Pages 82 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Prostate Cancer Diagnostics Quantitative research analysis
Global Prostate Cancer Diagnostics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Genomic Health (United States), Abbott (United States), OPKO (United States), Siemens Healthcare (Germany), DiaSorin (Italy), BioMeriux (France), Roche (Switzerlan), MDx Health (Belgium), Beckman Coulter (United States), Myriad Genetics (United States) and Ambry Genetics (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Emerging demand for Prostate Specific Antigen(PSA)testing" is seen as one of major influencing trends for Prostate Cancer Diagnostics Market during projected period 2023-2030.
The Prostate Cancer Diagnostics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Prostate Cancer Diagnostics Report?

Have a Query? Click Here

Other Related Reports

Brain Aneurysm Treatment Comprehensive Study by Type (Surgical Clipping, Endovascular Coiling, Flow diverters), Application (Hospitals, Clinics), Type (Unruptured Aneurysm, Ruptured Aneurysm) Players...
$ 3500
Membrane Filtration Systems Comprehensive Study by Type (Microfiltration (MF), Ultrafiltration (UF), Nanofiltration (NF), Reverse Osmosis (RO)), Application (Industrial Water And Wastewater Treatment...
$ 3450
Onychomycosis Comprehensive Study by Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candida Onychomycosis), Application (Children, Male Adult...
$ 3650
Sports Medicine Products Comprehensive Study by Type (Body reconstruction products, Body support & recovery products, Medical accessories), Application (Shoulder injuries, Foot and ankle injuries, El...
$ 3750
Tuberculin Comprehensive Study by Type (PPD-S, PPD RT23, Others), Application (Human Use, Animal Use), Therapy (First-Line Therapy, Second-Line Therapy) Players and Region - Global Market Outlook to ...
$ 3500
Homeopathy Comprehensive Study by Type (Tincture, Dilutions, Biochemics, Ointments, Tablets), Application (Respiratory, Neurology, Immunology, Gastroenterology, Dermatology, Others), Treatment (Auto-...
$ 3650